A previous study estimated that the sample size for a progressive MS trial on neuroprotective agents should be at least n = 173 for pRNFL and n = 125 for GCIP per trial arm for a 3-year study (power 80%, effect size 50%), numbers way larger than achieved in this exploratory outcome analysis (47). The gene discussed is CCNDBP1; the disease is myeloid sarcoma.